On 31 July 2018, orphan designation (EU/3/18/2045) was granted by the European Commission to Dystrogen Therapeutics S.A., Poland, for ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast for the treatment of Duchenne muscular dystrophy.
Ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast
|Disease / condition||
Treatment of Duchenne muscular dystrophy
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;